earningsconfidence high
Lineage Q1 2026 net loss $4.8M; cash $53.4M; new COR1 program launched
Lineage Cell Therapeutics, Inc.
2026-Q1 EPS
reported -$0.03
vs consensus -$0.02
▼ miss
(-47.1%)
- Net loss $4.8M ($0.02 basic/$0.03 diluted EPS) vs $4.1M loss in Q1 2025.
- Revenue $1.7M (+$0.2M YoY) driven by new WDI collaboration.
- Cash & marketable securities $53.4M; expected to fund ops into Q2 2028.
- Launched COR1 corneal endothelial cell therapy; second OPC1 spinal cord patient dosed.
- First AlloSCOPE 5D milestone achieved; Joachim Fruebis appointed founding SAB member.
item 2.02item 9.01
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.